Compare Alcon AG (ALC) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Herbalife Nutrition Ltd — how do they compare? Alcon AG trades at $66.88 (market cap $32.69B), while Herbalife Nutrition Ltd trades at $12.7 (market cap $1.36B). The key difference: Alcon AG is far larger — about 24× Herbalife Nutrition Ltd's market cap, and Alcon AG pays a 0.54% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| ALC | HLF | |
|---|---|---|
Market Cap | $32.69B | $1.36B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $19.96 |
52-Week Low | $62.02 | $7.75 |
Enterprise Value | $36.28B | $3.09B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Herbalife (HLF) trades at $13.14, showing modest daily gains of 0.23%. The stock presents a mixed technical picture with neutral signals from oscillators and bearish moving averages. Fundamentally, HLF maintains strong gross margins of 77.78% and attractive valuation metrics including a P/E of 5.64 and P/S of 0.26. Recent Q1 2026 earnings beat expectations with $0.64 EPS versus $0.607 expected, while the company completed a significant $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.
HLF offers value investment appeal with deep discount valuations and improving debt trends, though negative shareholder equity and competitive pressures in the nutrition space present ongoing challenges. Analyst sentiment leans bullish with 57.7% buy ratings, but the stock faces headwinds from its multi-level marketing model scrutiny and regional market volatility. The upcoming Q2 2026 earnings on August 5 will be crucial for validating recent guidance increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
